HK1170266A1 - 在人實體瘤中的基因缺損和突變體 激酶 - Google Patents

在人實體瘤中的基因缺損和突變體 激酶

Info

Publication number
HK1170266A1
HK1170266A1 HK12111020.7A HK12111020A HK1170266A1 HK 1170266 A1 HK1170266 A1 HK 1170266A1 HK 12111020 A HK12111020 A HK 12111020A HK 1170266 A1 HK1170266 A1 HK 1170266A1
Authority
HK
Hong Kong
Prior art keywords
alk
solid tumors
human solid
gene defects
mutant
Prior art date
Application number
HK12111020.7A
Other languages
English (en)
Inventor
Klarisa Rikova
Herbert Haack
Laura Sullivan
Ting-Lei Gu
Anthony Possemato
Ailan Guo
Joan Macneil
Jian Yu
Original Assignee
Cell Signaling Technology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40754049&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1170266(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cell Signaling Technology Inc filed Critical Cell Signaling Technology Inc
Publication of HK1170266A1 publication Critical patent/HK1170266A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
HK12111020.7A 2006-04-14 2012-11-01 在人實體瘤中的基因缺損和突變體 激酶 HK1170266A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79236406P 2006-04-14 2006-04-14

Publications (1)

Publication Number Publication Date
HK1170266A1 true HK1170266A1 (zh) 2013-02-22

Family

ID=40754049

Family Applications (2)

Application Number Title Priority Date Filing Date
HK12111020.7A HK1170266A1 (zh) 2006-04-14 2012-11-01 在人實體瘤中的基因缺損和突變體 激酶
HK18107824.7A HK1248280A1 (zh) 2006-04-14 2018-06-15 在人實體瘤中的基因缺損和突變體alk激酶

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK18107824.7A HK1248280A1 (zh) 2006-04-14 2018-06-15 在人實體瘤中的基因缺損和突變體alk激酶

Country Status (9)

Country Link
US (9) US7700339B2 (zh)
EP (4) EP2447359B1 (zh)
DK (2) DK2450437T3 (zh)
ES (2) ES2561406T3 (zh)
HK (2) HK1170266A1 (zh)
HU (1) HUE035732T2 (zh)
PL (1) PL2450437T3 (zh)
PT (1) PT2450437T (zh)
SI (1) SI2450437T1 (zh)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
EP2447359B1 (en) 2006-04-14 2015-11-04 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
US8168383B2 (en) 2006-04-14 2012-05-01 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
TWI389893B (zh) * 2007-07-06 2013-03-21 Astellas Pharma Inc 二（芳胺基）芳基化合物
AU2008317404B2 (en) * 2007-10-19 2014-12-18 Cell Signaling Technology, Inc. Cancer classification and methods of use
US20110110923A1 (en) * 2008-02-12 2011-05-12 The Brigham And Women's Hospital, Inc. Fish assay for eml4 and alk fusion in lung cancer
EP2487250A4 (en) * 2009-10-06 2013-03-20 Fujirebio Kk METHOD FOR DETECTION OF A FUSION GENE
TWI518325B (zh) * 2010-02-04 2016-01-21 自治醫科大學 對ａｌｋ抑制劑具有先抗性或後抗性癌症的識別、判斷和治療
TW201202703A (en) * 2010-04-16 2012-01-16 Response Genetics Inc Primers, probes, methods, and kits for the detection of EML4-ALK variants
WO2011146945A2 (en) * 2010-05-21 2011-11-24 Cell Signaling Technology, Inc. Alk and ros kinase in cancer
US20120101108A1 (en) 2010-08-06 2012-04-26 Cell Signaling Technology, Inc. Anaplastic Lymphoma Kinase In Kidney Cancer
WO2012075318A2 (en) * 2010-12-01 2012-06-07 Cell Signaling Technology, Inc. Fn1 and alk gene translocations in cancer and alk kinase expression in ovarian cancer
CA2823337C (en) * 2010-12-29 2019-09-10 Expression Pathology, Inc. Her3 protein srm/mrm assay
WO2012106559A1 (en) * 2011-02-02 2012-08-09 Translational Genomics Research Institute Biomarkers and methods of use thereof
US9150929B2 (en) * 2011-05-17 2015-10-06 The Johns Hopkins University Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene
US20140315943A1 (en) 2011-05-24 2014-10-23 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mtor/p13k inhibitors
EP2729144A2 (en) 2011-07-07 2014-05-14 Synta Pharmaceuticals Corp. Treating cancer with hsp90 inhibitory compounds
WO2013059740A1 (en) * 2011-10-21 2013-04-25 Foundation Medicine, Inc. Novel alk and ntrk1 fusion molecules and uses thereof
CA2853799A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
CA2853806C (en) 2011-11-02 2020-07-14 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with platinum-containing agents
US9402831B2 (en) 2011-11-14 2016-08-02 Synta Pharmaceutical Corp. Combination therapy of HSP90 inhibitors with BRAF inhibitors
SI2838998T1 (en) 2012-04-18 2018-04-30 Cell Signaling Technology, Inc. EGFR AND ROS1 PRI CRAK
WO2013170182A1 (en) 2012-05-11 2013-11-14 Synta Pharmaceuticals Corp. Treating cancer with an hsp90 inhibitory compound
WO2014036387A2 (en) * 2012-08-31 2014-03-06 The Regents Of The University Of Colorado Methods for diagnosis and treatment of cancer
WO2014071358A2 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
WO2014071419A2 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
EP2945652B1 (en) 2013-01-18 2021-07-07 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
US10597725B2 (en) 2014-09-01 2020-03-24 Arkray, Inc. Primer reagent for amplifying ALK fusion gene, ALK fusion gene amplification reagent kit including the same, and ALK fusion gene amplification method and ALK fusion gene analysis method using the same
EP3256161A1 (en) 2015-02-09 2017-12-20 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors and pd-1 inhibitors for treating cancer
WO2017207696A1 (en) 2016-06-01 2017-12-07 F. Hoffmann-La Roche Ag Novel mutations in anaplastic lymphoma kinase predicting response to alk inhibitor therapy in lung cancer patients
AU2018277210B2 (en) * 2017-05-31 2024-03-28 F. Hoffmann-La Roche Ag Multiplex PCR detection of ALK, RET, and ROS fusions
JP7385191B2 (ja) 2019-08-30 2023-11-22 学校法人同志社 Ｅｍｌ４－ａｌｋ阻害ペプチドおよびこれを含む肺がん治療薬
EP4165186A1 (en) * 2020-06-16 2023-04-19 Alnylam Pharmaceuticals, Inc. Anaplastic lymphoma kinase (alk) irna agent compositions and methods of use thereof

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3023787A1 (de) 1980-06-25 1982-01-21 Studiengesellschaft Kohle mbH, 4330 Mülheim Verfahren zur erhoehung der inkorporation und der expression von genetischem material in die kerne von intakten zellen mit hilfe von liposomen
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4659678A (en) 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4727022A (en) 1984-03-14 1988-02-23 Syntex (U.S.A.) Inc. Methods for modulating ligand-receptor interactions and their application
JPH07119760B2 (ja) 1984-07-24 1995-12-20 コモンウエルス・セ−ラム・ラボラトリ−ズ・コミッション ミモトープを検出または決定する方法
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
DK0452457T3 (da) 1989-11-03 1998-03-02 Univ Vanderbilt Fremgangsmåde til in vivo fjernelse af funktionelle fremmede gener
ES2225816T5 (es) 1990-02-01 2014-08-21 Siemens Healthcare Diagnostics Products Gmbh Producción y utilización de bancos de genes de anticuerpos humanos ("bibliotecas de anticuerpos humanos")
DE4002897A1 (de) 1990-02-01 1991-08-08 Behringwerke Ag Herstellung und verwendung von genbanken synthetischer menschlicher antikoerper ("synthetische human-antikoerper-bibliotheken")
WO1994002595A1 (en) 1992-07-17 1994-02-03 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of animal diseases
US6710174B2 (en) 2001-09-13 2004-03-23 Isis Pharmaceuticals, Inc. Antisense inhibition of vascular endothelial growth factor receptor-1 expression
IL108367A0 (en) 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
US6340674B1 (en) 1993-03-26 2002-01-22 Thomas Jefferson University Method of inhibiting the proliferation and causing the differentiation of cells with IGF-1 receptor antisense oligonucleotides
US5480971A (en) 1993-06-17 1996-01-02 Houghten Pharmaceuticals, Inc. Peralkylated oligopeptide mixtures
US5529925A (en) * 1993-12-03 1996-06-25 St. Jude Children's Research Hospital Nucleic acid sequences and fusion proteins present in human t(2;5) lymphoma
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5753613A (en) 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5783683A (en) 1995-01-10 1998-07-21 Genta Inc. Antisense oligonucleotides which reduce expression of the FGFRI gene
US5675063A (en) 1995-02-28 1997-10-07 Loyola University Of Chicago Immortalized rabbit hybridoma fusion partner
WO1997008320A1 (en) 1995-08-18 1997-03-06 Morphosys Gesellschaft Für Proteinoptimierung Mbh Protein/(poly)peptide libraries
US6395713B1 (en) 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
US6617162B2 (en) 2001-12-18 2003-09-09 Isis Pharmaceuticals, Inc. Antisense modulation of estrogen receptor alpha expression
WO1999031262A2 (en) 1997-12-16 1999-06-24 Valentis, Inc. Needle-free injection of formulated nucleic acid molecules
US6302838B1 (en) 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
US7198896B2 (en) 1998-09-04 2007-04-03 Cell Signaling Technology, Inc. Immunoaffinity isolation of modified peptides from complex mixtures
US7300753B2 (en) 1998-09-04 2007-11-27 John Rush Immunoaffinity isolation of modified peptides from complex mixtures
WO2000053722A2 (en) 1999-03-10 2000-09-14 Phogen Limited Delivery of nucleic acids and proteins to cells
US7662793B2 (en) 1999-06-18 2010-02-16 University Of Pittsburgh Of The Commonwealth System Of Higher Education Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from a Pol III promoter
US6472153B1 (en) 1999-10-26 2002-10-29 Epoch Biosciences, Inc. Hybridization-triggered fluorescent detection of nucleic acids
US7829693B2 (en) 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
IL151928A0 (en) 2000-03-30 2003-04-10 Whitehead Biomedical Inst Rna sequence-specific mediators of rna interference
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
JP4095895B2 (ja) 2000-12-01 2008-06-04 マックス−プランク−ゲゼルシャフト ツール フォーデルング デル ヴィッセンシャフテン エー．ヴェー． Ｒｎａ干渉を媒介する短鎖ｒｎａ分子
HUP0302525A2 (hu) 2001-01-05 2003-10-28 Abgenix, Inc. Az inzulinszerű növekedési faktor I receptor elleni ellenanyagok
JP2005514002A (ja) 2001-05-17 2005-05-19 ザ パブリック ヘルス リサーチ インスティテュート オブ ザ シティ オブ ニューヨーク，インコーポレーテッド Ｒｎａをアンチセンス攻撃するための標的部位の選択
US20040209832A1 (en) 2001-11-30 2004-10-21 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20030170891A1 (en) 2001-06-06 2003-09-11 Mcswiggen James A. RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA)
WO2002102854A2 (en) 2001-06-20 2002-12-27 Morphosys Ag Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
US20030099974A1 (en) * 2001-07-18 2003-05-29 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer
WO2003016861A2 (en) 2001-08-14 2003-02-27 President And Fellows Of Harvard College Absolute quantification of proteins and modified forms thereof by multistage mass spectrometry
US20030219839A1 (en) 2001-09-20 2003-11-27 Katherine Bowdish Anti-PDGF antibodies and methods for producing engineered antibodies
US6734017B2 (en) 2001-09-28 2004-05-11 Isis Pharmaceuticals, Inc. Antisense modulation of vascular endothelial growth factor receptor-2 expression
DE10230997A1 (de) 2001-10-26 2003-07-17 Ribopharma Ag Medikament zur Erhöhung der Wirksamkeit eines Rezeptor-vermittelt Apoptose in Tumorzellen auslösenden Arzneimittels
JP2006508899A (ja) 2002-05-20 2006-03-16 アブジエニツクス・インコーポレイテツド ＥＧＦｒに対する抗体を使用する腎癌の治療方法
US20040023390A1 (en) 2002-08-05 2004-02-05 Davidson Beverly L. SiRNA-mediated gene silencing with viral vectors
WO2004050681A2 (en) 2002-11-15 2004-06-17 Exelixis, Inc. Kinase modulators
ES2401330T3 (es) 2003-02-26 2013-04-18 Sugen, Inc. Compuesto de heteroarilamino inhibidores de proteín quinasas
ES2263862T3 (es) 2003-03-07 2006-12-16 Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Ensayo de quinasa de linfoma anaplasico, sus reactivos y composiciones.
BRPI0408317A (pt) 2003-03-14 2006-03-07 Pharmacia Corp anticorpos do receptor de igf-i para o tratamento de cáncer
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
EP1648455A4 (en) 2003-07-23 2009-03-04 Exelixis Inc MODULATORS OF ALK PROTEIN (ANAPLASTIC LYMPHOMA KINASE) AND METHODS OF USE
MY147449A (en) 2003-08-15 2012-12-14 Novartis Ag 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
GB0321710D0 (en) 2003-09-16 2003-10-15 Novartis Ag Organic compounds
JP2007505858A (ja) 2003-09-18 2007-03-15 ノバルティス アクチエンゲゼルシャフト 増殖性障害の処置に有用な２，４−ジ（フェニルアミノ）ピリミジン
EP2418281B1 (en) 2003-10-24 2016-06-01 Gencia Corporation Methods and compositions for delivering polynucleotides
AU2004295061B2 (en) 2003-11-21 2008-11-20 Novartis Ag 1H-imidazoquinoline derivatives as protein kinase inhibitors
JP4989233B2 (ja) 2004-02-14 2012-08-01 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
US20050214301A1 (en) 2004-03-24 2005-09-29 Cell Signaling Technology, Inc. Antibodies specific for BCR-ABL fusion protein and uses thereof
US7973061B2 (en) 2004-03-31 2011-07-05 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
JP4691549B2 (ja) 2004-04-07 2011-06-01 ノバルティス アーゲー Ｉａｐの阻害剤
BRPI0513915A (pt) 2004-08-26 2008-05-20 Pfizer compostos aminoeteroarila enantiomericamente puros como inibidores de proteìna quinase
GB0419160D0 (en) 2004-08-27 2004-09-29 Novartis Ag Organic compounds
GB0419161D0 (en) 2004-08-27 2004-09-29 Novartis Ag Organic compounds
JP3884462B2 (ja) 2005-10-14 2007-02-21 株式会社ファースト 高速画像探索方法
SI1959955T1 (sl) 2005-12-05 2011-02-28 Pfizer Prod Inc Postopek zdravljenja abnormalne celične rasti
JP2007265917A (ja) 2006-03-29 2007-10-11 Toshiba Corp Ｘ線管及びその制御方法
US8168383B2 (en) 2006-04-14 2012-05-01 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
EP2447359B1 (en) 2006-04-14 2015-11-04 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
EP1914240B1 (en) * 2006-10-11 2009-12-02 Astellas Pharma Inc. EML4-ALK fusion gene
CA2598893C (en) * 2006-10-11 2012-04-10 Astellas Pharma Inc. Eml4-alk fusion gene
KR101362284B1 (ko) 2007-04-13 2014-02-12 셀 시그널링 테크놀러지, 인크. 인간 고형 종양에서 유전자 결손 및 돌연변이 ａｌｋ 카이네이즈
US20110110923A1 (en) 2008-02-12 2011-05-12 The Brigham And Women's Hospital, Inc. Fish assay for eml4 and alk fusion in lung cancer
AU2010248782B2 (en) 2009-05-15 2015-06-11 Insight Genetics, Inc. Methods and compositions relating to fusions of ALK for diagnosing and treating cancer

Also Published As

Publication number Publication date
US20110223609A1 (en) 2011-09-15
US20100304382A1 (en) 2010-12-02
SI2450437T1 (sl) 2017-12-29
US10870892B2 (en) 2020-12-22
EP3266867A1 (en) 2018-01-10
US9988688B2 (en) 2018-06-05
DK2447359T3 (en) 2016-02-08
US8232060B2 (en) 2012-07-31
US7700339B2 (en) 2010-04-20
DK2450437T3 (en) 2017-09-11
US20110021546A1 (en) 2011-01-27
EP2447360A1 (en) 2012-05-02
PT2450437T (pt) 2017-08-25
US20090156475A1 (en) 2009-06-18
US20210371933A1 (en) 2021-12-02
US20190127804A1 (en) 2019-05-02
US9523130B2 (en) 2016-12-20
PL2450437T3 (pl) 2017-12-29
ES2637592T3 (es) 2017-10-13
HUE035732T2 (en) 2018-05-28
EP2447359B1 (en) 2015-11-04
EP2450437A2 (en) 2012-05-09
ES2561406T3 (es) 2016-02-26
US20160333425A1 (en) 2016-11-17
US11505833B2 (en) 2022-11-22
US20160186268A1 (en) 2016-06-30
US8288102B2 (en) 2012-10-16
HK1248280A1 (zh) 2018-10-12
US8377642B2 (en) 2013-02-19
US20130209452A1 (en) 2013-08-15
EP2450437A3 (en) 2012-08-01
EP2450437B1 (en) 2017-05-17
EP2447359A1 (en) 2012-05-02

Similar Documents

Publication Publication Date Title
HK1248280A1 (zh) 在人實體瘤中的基因缺損和突變體alk激酶
HK1122040A1 (zh) 人實體瘤中的基因缺陷和突變 激酶
HK1256305A1 (zh) 人非小細胞肺癌中的易位和突變的ros激酶
EP2076128A4 (en) PROTEIN CHINESE INHIBITOR AND ITS USE METHOD
ZA201001738B (en) Lacrimal implants and related methods
ZA200905886B (en) Methods and kits for administering probiotics
GB2467830B (en) Mutant proteins and methods for producing them
ZA200810290B (en) Grain refiners for steel-manufacturing methods and use
EP1934361A4 (en) METHODS OF REJUVENING IN VITRO AND IN VIVO CELLS
EP2114983B8 (en) Axl tyrosine kinase inhibitors and methods of making and using the same
HK1137448A1 (zh) 絲氨酸-蘇氨酸蛋白激酶和 調節劑
HK1117407A1 (zh) 用於增强成像對比度的組合物和方法
ZA200701635B (en) Quinazolinone derivatives and their use as B-Raf inhibitors
ZA200900905B (en) Modified-galactosyl ceramides for staining and stimulating Natural Killer T cells
EP1940454A4 (en) ORAL PREPARATION FOR ENTERIC DISORDERS AND / OR REHYDRATION
ZA200701366B (en) Quinazolinone derivatives and their use as B-Raf inhibitors
EP1919331A4 (en) WASHABLE PILLOW AT ADJUSTABLE HEIGHT
GB0802474D0 (en) Mutant proteins and methods for selecting them
PL2223121T3 (pl) Sposób różnicowania NZJ i ZJD oraz dalsze rozróżnienie odmian NZJ
EP2203558A4 (en) TRANSLOCATION AND MUTANT ROS KINASE IN HUMAN LARGE CELL PULMONARY EPITHELIAMA
HK1156836A1 (zh) 淚腺植入物及相關方法
EP1960534A4 (en) ENZYMATIC METHODS FOR MEASURING THE SPHINGOMYLELIN AND PHOSPHATIDYLCHOLIN SHARE IN PLASMA AND TISSUE
EP2045245A4 (en) IRREVERSIBLE TYROSINE KYNASES INHIBITORS AND METHODS OF PREPARATION AND USES THEREOF
EP2357229A4 (en) HYDROXYLASE GENE AND USE THEREOF
GB2447003B (en) Alpha-galactosidase from bifidobacterium bifidum and its use